Процеси вільнорадикального окиснення при лікуванні пацієнтів із одонтогенними флегмонами щелепно-лицевої локалізації на тлі ішемічної хвороби серця

Abstract

Питанням оптимізації лікування одонтогенних флегмон щелепно-лицевої локалізації займається велика когорта вчених. На перебіг даних захворювань має вплив значна низка чинників, одним із яких є ішемічна хвороба серця. Потужним антиоксидантом з вираженою антиоксидантною дією є кверцетин. Використання 2-етил-6-метил-3-гідроксипіридину сукцинату призводить до посилення окислюваності компонентів, тобто до синергічного антиоксидантного ефекту. Мета досліджен-ня: покращити медикаментозне лікування одонтогенних флегмон щелепно-лицевої локалізації у пацієнтів із ішемічною хворобою серця шляхом комбінованого застосування препаратів, що мають антиоксидантну, антигіпоксантну та ангіопротекторну дію. Матеріали та методи дослідження. Обстежено 80 пацієнтів з одонтогенними флегмона щелепно-лицевої локалізації

A large cohort of scientists is dealing with the issue of improving the treatment of maxillofacial odontogenic phlegmons. The course of these diseases is impacted by a significant number of factors, one of which is ishemic heart disease. Quercetin is a powerful antioxidant with a pronounced antioxidant effect. The use of 2-ethyl-6-methyl-3-hydroxypyridine succinate leads to increased oxidation of components, that is, to a synergistic antioxidant effect. The purpose of this study is to enhance the therapy of odontogenic phlegmons of maxillofacial area in patients with ishemic heart disease through the combined use of drugs with antioxidant, antihypoxant and angioprotective effects. Materials and methods. 80 patients with odontogenic phlegmon of maxillofacial area were examined. The participants were categorized into the following groups: Group 1 received parenteral quercetin, Group 2 received a combination of quercetin and intravenous administration of 2-ethyl-6-methyl-3-hydroxypyridine succinate, Group 3 received standard treatment (20 individuals), and Group 4 (control) comprised individuals without concomitant pathology who received the treatment according to a standard protocol (20 patients). To analyze the state of free radical oxidation processes in blood serum, the content of diene conjugates was studied. Results. The level of diene conjugates was increased when compared to the control group by 93.2%, 95.0% and 96.2% for the 1st, 2nd and 3rd clinical groups, respectively. On the third day of observation, patients with coronary heart disease displayed an increase in the studied indicator by 99.1%, 100.6%, and 97.8%, respectively, compared to the controls. After 5 days, in all four clinical groups, there was a decrease in diene conjugates content in blood serum compared to the previous observation period by 6.9%, 8.2%, 5.3% and 11.8%, respectively. A tendency to a gradual decrease in the content of diene conjugates was observed on the 7th day of observation in all groups by 5.5%, 6.8%, 4.2% and 11.8%, respectively, with its increase relative to the control by 112.9 %, 108.7% and 118.2% for the 1st, 2nd and 3rd clinical groups, respectively. On the 9th day of observation, a decrease in DC content by 2.7% was found only in patients of the 2nd clinical group. At the final follow-up period, a decrease in this marker was noted in all studied clinical groups relative to the previous follow-up period by 5.1%, 6.9%, 2.3%, and 9.7%, respectively. Conclusion: Under the combined administration of quercetin and 2-ethyl-6-methyl-3-hydroxypyridine succinate alongside a standard treatment protocol, the reduction in the level of diene conjugates in blood serum was most significant among patients with coronary heart disease, particularly in the later stages following surgical treatment.